Epigenomics AG reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was EUR 0.339227 million compared to EUR 0.899 million a year ago. Net loss was EUR 4.46 million compared to EUR 1,730.4 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.695 EUR | +2.73% | +2.73% | -10.32% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-10.32% | 1.57M | |
-32.63% | 9.98B | |
+23.12% | 2.87B | |
-18.33% | 2.07B | |
-24.39% | 1.59B | |
+65.65% | 1.43B | |
+32.83% | 824M | |
-6.77% | 733M | |
-29.80% | 508M | |
+0.40% | 296M |
- Stock Market
- Equities
- ECX Stock
- News Epigenomics AG
- Epigenomics AG Reports Earnings Results for the Full Year Ended December 31, 2023